Atara Biotherapeutics’s robust, late-stage pipeline features a host of potentially transformative T-cell immunotherapies for cancer and autoimmune diseases. Tabelecleucel (tab-cel®) is in Phase 3 development for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disease (EBV+ PTLD) as well as in earlier stage development for other EBV-associated diseases.
Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
RR EBV+ PTLD following SOT or HCT |
ALLELE
|
Study
|
||
|
||||
Multi-cohort: EBV+ cancers |
ALLELE
|
Study
|
||
|
||||
Nasopharyngeal carcinoma (NPC) |
ALLELE
|
|||
|
Indication | Phase |
---|---|
RR EBV+ PTLD following SOT or HCT | Phase 3 |
|
|
Multi-cohort: EBV+ cancers | Phase 1 |
|
|
Nasopharyngeal carcinoma (NPC) | Phase 2 |
|
Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
Progressive MS |
EMBOLD Study
|
|||
|
Indication | Phase |
---|---|
Progressive MS | Phase 2 |
|
Program/Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
ATA2271: Mesothelioma & other solid tumors | ||||
|
||||
ATA3271: Mesothelioma & other solid tumors | ||||
|
Program/Indication | Phase |
---|---|
ATA2271: Mesothelioma & other solid tumors | Phase 1 |
|
|
ATA3271: Mesothelioma & other solid tumors | Preclinical |
|
Program/Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
ATA3219: B-cell malignancies | ||||
|
Program/Indication | Phase |
---|---|
ATA3219: B-cell malignancies | Preclinical |
|
Program/Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
ATA2431: B-cell malignancies | ||||
|
||||
Solid Tumor and Infectious disease CAR T programs | ||||
|
Program/Indication | Phase |
---|---|
ATA2431: B-cell malignancies | Preclinical |
|
|
Solid Tumor and Infectious disease CAR T programs | Preclinical |
|
T-cell immunotherapy for EBV-associated ultra-rare diseases
FDA breakthrough designation & EMA PRIME for EBV+ PTLD
EBV CD19 CAR T
Next-generation off-the-shelf, allogeneic CD19-1XX CAR+ EBV T-cell immunotherapy containing a modified CD3ζ signaling domain, 1XX
Building upon years of ground-breaking clinical research of collaborators enables us to harness the potential of allogeneic technology and develop unique, off-the-shelf T-cell immunotherapies for the treatment of patients suffering from cancer and certain autoimmune diseases.